{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:46Z","timestamp":1761871066180,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clml.2017.06.031","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:47:46Z","timestamp":1498693666000},"page":"774-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Justyna","family":"Bartoszko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Panzarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Jane","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5345-8328","authenticated-orcid":false,"given":"Anthea","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Maze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen W.L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.031_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2017.06.031_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CLEP.S47150","article-title":"The impact of comorbidity on cancer survival: a review","volume":"5","author":"Sogaard","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.06.031_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbach","year":"2014","journal-title":"Exert Rev Hematol"},{"key":"10.1016\/j.clml.2017.06.031_bib4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3109\/10428194.2013.879127","article-title":"Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.031_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cam4.136","article-title":"Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review","volume":"2","author":"Mitra","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2017.06.031_bib6","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.031_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2009.02.007","article-title":"Validation of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) in single and multiple institutions: limitations and inferences","volume":"15","author":"Sorror","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.031_bib8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Heamatol"},{"key":"10.1016\/j.clml.2017.06.031_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jgo.2012.01.006","article-title":"Comparison of scoring methods for ACE-27: simpler is better","volume":"3","author":"Kallogjeri","year":"2012","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clml.2017.06.031_bib10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bmt.2016.141","article-title":"Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation","volume":"51","author":"Elsawy","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.031_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2010.1.237","article-title":"Comorbidities and hematopoietic cell transplantation outcomes","volume":"2010","author":"Sorror","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2017.06.031_bib12","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood.V124.21.1828.1828","article-title":"Comorbidity scales in patients with myeloproliferative neoplasms: which one fits best?","volume":"124","author":"Isfort","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.031_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jamcollsurg.2014.01.059","article-title":"Comparison of comorbidity collection methods","volume":"219","author":"Kallogjeri","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.clml.2017.06.031_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ajh.23675","article-title":"Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes","volume":"89","author":"Daver","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.031_bib15","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.ejca.2014.09.016","article-title":"Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index","volume":"50","author":"Van Spronsen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2017.06.031_bib16","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.031_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.031_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.031_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12032-014-0869-8","article-title":"Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2017.06.031_bib20","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.28857","article-title":"Comorbidities predict worse prognosis in patients with primary myelofibrosis","volume":"20","author":"Newberry","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.031_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.031_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:00Z","timestamp":1761870600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2152265017308303"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.031","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}